Characteristics of study population
| Characteristics . | Percentage of enrollees . |
|---|---|
| n | 900 |
| Age (years) | |
| <45 | 19.7 |
| 45–54 | 38.5 |
| 55–64 | 32.9 |
| ≥65 | 8.9 |
| Sex | |
| Male | 55.2 |
| Female | 44.8 |
| Single versus multiple oral therapy in 2000 | |
| Multiple therapies | 45.8 |
| Single therapy | 54.2 |
| Nonadherence to medications in 2000 (MPR <80%) | |
| Antihyperglycemic | 28.8 |
| Antihypertensive | 18.8 |
| Lipid-modifying | 26.9 |
| Charlson comorbidity index | |
| 1 | 67.1 |
| 2–3 | 25.3 |
| ≥4 | 7.6 |
| Hospitalizations | |
| 2000 (all cause) | 11.4 |
| 2001 (diabetes/CVD)* | 6.7 |
| Characteristics . | Percentage of enrollees . |
|---|---|
| n | 900 |
| Age (years) | |
| <45 | 19.7 |
| 45–54 | 38.5 |
| 55–64 | 32.9 |
| ≥65 | 8.9 |
| Sex | |
| Male | 55.2 |
| Female | 44.8 |
| Single versus multiple oral therapy in 2000 | |
| Multiple therapies | 45.8 |
| Single therapy | 54.2 |
| Nonadherence to medications in 2000 (MPR <80%) | |
| Antihyperglycemic | 28.8 |
| Antihypertensive | 18.8 |
| Lipid-modifying | 26.9 |
| Charlson comorbidity index | |
| 1 | 67.1 |
| 2–3 | 25.3 |
| ≥4 | 7.6 |
| Hospitalizations | |
| 2000 (all cause) | 11.4 |
| 2001 (diabetes/CVD)* | 6.7 |
CVD represents both cardiovascular and cerebrovascular events.